SELLAS Life Sciences Reports Positive Topline Data In Lymphoma Cohort From SLS009 Phase 1 Trial
(RTTNews) - SELLAS Life Sciences Group, Inc. (SLS) announced Thursday positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from the Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009).
The trial successfully achieved all primary and secondary study objectives, including safety, clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD).
The recommended Phase 2 Dose (RP2D) for lymphoma patients has been established at the highest dose level evaluated of 100 mg, administered as a once-weekly infusion. The maximum tolerated dose (MTD) was not reached.
A dose-limiting toxicity occurred in one out of five patients treated at the 100 mg dose level. No dose-limiting toxicities were observed at any other dose level, and there were no unexpected toxicities across the study.
A total of 52 r/r lymphoma patients were enrolled. Of these, 24 received two bi-weekly doses (BIW), while 28 were administered weekly doses (QW). Among the 52 r/r lymphoma patients, 15 were diagnosed with PTCL, with 6 of them receiving the BIW regimen and 9 the QW regimen.
The dose-escalation trial investigated a range of doses from 2.5 mg to 100 mg, employing two dosing regiments: once-weekly infusions (QW) and twice-weekly infusions (BIW).
SELLAS Says FDA Grants Rare Pediatric Disease Designation For SLS009 To Treat Pediatric ALL
U.S. Consumer Sentiment Drops Less Than Previously Estimated In September
Bay Street Poised For Positive Open On Metal Gains
U.S. Durable Goods Orders Unexpectedly Unchanged In August
FTSE 100 Edges Higher On Mining, Banking Strength
Canadian Dollar Falls As Crude Oil Prices Slide
CAC 40 Pares Early Gains, Down Marginally
